---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-082819"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:30:39.691444+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Kalaris Therapeutics enters new CEO employment agreement with severance benefits; CAO severance set

## Summary
- CEO Oxtoby's new base salary is $569,100; target bonus up to 55% of base salary.
- On non-CIC termination without cause/good reason: 12 months base salary plus COBRA.
- On CIC termination: 18 months base salary, 150% target bonus lump sum, 18 months COBRA, full equity acceleration.
- CAO Hagen gets 9 months base salary (non-CIC) or 12 months plus 100% target bonus lump sum (CIC) and equity acceleration.
- Both agreements require release and continued compliance with restrictive covenants.

## SEC filing metadata
- accession: 0001193125-25-082819
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525082819/0001193125-25-082819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525082819/d949516d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-082819
- JSON: https://secwatch.observer/filing/0001193125-25-082819.json
- Plain text: https://secwatch.observer/filing/0001193125-25-082819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.